Market Cap
US$71.8m
Last Updated
2021/01/17 00:28 UTC
Data Sources
Company Financials +
Executive Summary
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Biocept's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
4.1%
BIOC
3.5%
US Biotechs
-1.0%
US Market
1 Year Return
54.2%
BIOC
36.8%
US Biotechs
19.6%
US Market
Shareholder returns
| BIOC | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.1% | 3.5% | -1.0% |
| 30 Day | 1.1% | 4.5% | 2.2% |
| 90 Day | 14.0% | 19.2% | 11.5% |
| 1 Year | 54.2%54.2% | 39.0%36.8% | 22.3%19.6% |
| 3 Year | -97.3%-97.3% | 30.5%23.6% | 45.3%35.7% |
| 5 Year | -99.6%-99.6% | 43.9%33.0% | 124.8%99.8% |
Long-Term Price Volatility Vs. Market
How volatile is Biocept's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?2 months ago | Simply Wall St
Is Biocept (NASDAQ:BIOC) In A Good Position To Invest In Growth?6 months ago | Simply Wall St
We Think Biocept (NASDAQ:BIOC) Needs To Drive Business Growth CarefullyValuation
Is Biocept undervalued compared to its fair value and its price relative to the market?
3.36x
Price to Book (PB) ratio
Share Price vs. Fair Value
Price To Earnings Ratio
Price to Earnings Growth Ratio
Price to Book Ratio
Next Steps
Future Growth
How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
66.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings per Share Growth Forecasts
Future Return on Equity
Next Steps
Past Performance
How has Biocept performed over the past 5 years?
-10.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Return on Equity
Next Steps
Financial Health
How is Biocept's financial position?
Financial Position Analysis
Debt to Equity History and Analysis
Balance Sheet
Next Steps
Dividend
What is Biocept current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Stability and Growth of Payments
Current Payout to Shareholders
Future Payout to Shareholders
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Mike Nall (57 yo)
7.42yrs
Tenure
US$1,216,055
Compensation
Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, ...
CEO Compensation Analysis
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.42yrs | US$1.22m | 0.0031% $ 2.2k | |
| CFO, Senior VP of Operations & Corporate Secretary | 4.5yrs | US$826.51k | 0.0022% $ 1.5k | |
| 24yrs | no data | no data | ||
| Director of Technology Development | 3.33yrs | no data | no data | |
| General Counsel and Compliance & Privacy Officer | 3.25yrs | no data | no data | |
| Vice President of Strategy & Corporate Communications | 4.25yrs | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Senior Director of Marketing | 1yr | no data | no data | |
| Senior Director of People & Culture/Facilities | 1yr | no data | no data | |
| Senior Medical Director | 6.08yrs | US$115.22k | no data | |
| Senior VP | 0.42yr | no data | 0.0043% $ 3.1k |
3.8yrs
Average Tenure
57yo
Average Age
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.42yrs | US$1.22m | 0.0031% $ 2.2k | |
| Interim Chair & Lead Independent Director | 1yr | US$82.25k | 0.00057% $ 409.3 | |
| Independent Director | 11yrs | US$67.25k | 0.00043% $ 308.8 | |
| Director | 9.83yrs | US$128.50k | 0.0033% $ 2.4k | |
| Member of Scientific Advisory Board | no data | US$287.43k | 0.0022% $ 1.6k | |
| Independent Director | 0.25yr | no data | no data | |
| Chairwoman Emeritus | 9.75yrs | no data | no data | |
| Independent Director | 7.17yrs | US$66.00k | 0.00017% $ 122.1 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 10.25yrs | US$64.75k | 0.0024% $ 1.7k |
8.9yrs
Average Tenure
72yo
Average Age
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Recent Insider Transactions
Ownership Breakdown
Top Shareholders
Company Information
Biocept, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biocept, Inc.
- Ticker: BIOC
- Exchange: NasdaqCM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$71.807m
- Shares outstanding: 13.40m
- Website: https://biocept.com
Number of Employees
Location
- Biocept, Inc.
- 9955 Mesa Rim Road
- San Diego
- California
- 92121
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BIOC | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Feb 2014 |
| B002 | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Feb 2014 |
| B003 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/17 00:28 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.